Category

UF COVID-19

UF Health Expert Discusses COVID-19 Booster Shots

Michael Lauzardo, M.D., deputy director of UF’s Emerging Pathogens Institute and an associate professor in the UF College of Medicine’s department of medicine, talks about issues related to the third vaccine dose. 

Oragenics’ SARS-CoV-2 Spike Protein Produces Neutralizing Antibodies in Mice With Intramuscular and Intranasal Adjuvants

UF startup and UF Innovate | Sid Martin Biotech graduate Oragenics, Inc., a leader in the development of new antibiotics against infectious diseases and effective treatments for oral mucositis, announces that the stabilized pre-fusion spike protein trimer produced by its Canadian collaborator and licensed by the company from the National Institutes of Health (NIH) generates neutralizing antibodies in mice after immunization against SARS-CoV-2, when administered with several novel intramuscular (IM) and intranasal (IN) adjuvants.

Two-Year Backlog in Biologicals Manufacturing Hinders Medical R&D, Development of New Therapies for COVID-19

One area where COVID-19 has had a substantial impact is the development and manufacturing of medicines, medical devices, and pharmaceutical products. The CDMO industry is showing enormous growth and is projected to become a $315 billion industry by 2026. However, the demand for products skyrocketed so quickly that supply has not been able to keep pace. According to Dr. Ian White, president and CSO of Neobiosis, a UF Innovate | Sid Martin Biotech resident company that focuses on the science of regenerative medicine, demand has caused a two-year backlog of desperately needed cellular and acellular products for use in research and clinical trials directed at treating the COVID-19 virus and its complications (AKA Post-COVID Syndrome).